



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/82, 7/06, A61K 38/08	A1	(11) International Publication Number: WO 99/10382 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/NO98/00252 (22) International Filing Date: 26 August 1998 (26.08.98) (30) Priority Data: 9718110.1 27 August 1997 (27.08.97) GB (71) Applicant (for all designated States except US): NORSK HYDRO ASA [NO/NO]; N-0240 Oslo (NO). (72) Inventors; and (75) Inventors/Applicants (for US only): GAUDERNACK, Gustav [NO/NO]; Det Norske Radiumhospitalet, Ullernch. 70, N-0310 Oslo (NO). GJERTSEN, Marianne, Klemp [NO/NO]; Det Norske Radiumhospitalet, Ullernch. 70, N-0310 Oslo (NO). ERIKSEN, Jon, Amund [NO/NO]; Bjørmtvedtgt. 37, N-3900 Porsgrunn (NO). (74) Agent: LILLEGRAVEN, Rita; Norsk Hydro ASA, N-0240 Oslo (NO).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PEPTIDES WHICH ELICIT CYTOTOXIC T CELLULAR IMMUNITY (57) Abstract Synthetic peptides of oncogene protein products which elicit cytotoxic T cellular immunity, for use in cancer vaccines and compositions for anti-cancer treatment.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PEPTIDES WHICH ELICIT CYTOTOXIC T CELLULAR IMMUNITYSummary of the invention

5 This invention relates to synthetic peptides corresponding to p21 ras oncogene protein products which elicit cytotoxic T cellular immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising said peptides, as well as methods for the treatment or
10 prophylaxis of cancers arising from activated ras oncogenes.

The present invention represents a further development of anti-cancer treatment or prophylaxis based on using the
15 body's own immune system through an activation and strengthening of the immune response from specific cytotoxic T cells.

Technical Background

20 The genetic background for the onset of cancer are proto-oncogenes and oncogenes. Proto-oncogenes are normal genes of the cell which have the potential of becoming oncogenes. All oncogenes code for and function through a protein. Oncogenes arise in nature from proto-oncogenes
25 through point mutations or translocations, thereby resulting in a transformed state of the cell harbouring the mutation. Cancer develops through a multistep process involving several mutational events and oncogenes.

30 In its simplest form a single base substitution in a proto-oncogene may cause the resulting gene product to differ in one amino acid only.

It has been shown that point mutations in intracellular "self"-proteins may give rise to tumour rejection
35 antigens, consisting of peptides differing in a single amino acid from the normal peptide. The T cells which recognise these peptides in the context of the major histocompatibility (MHC) molecules on the surface of the

tumour cells, are capable of killing the tumour cells and thus rejecting the tumour from the host.

5 In contrast to antibodies produced by the B cells, which typically recognise an antigen in its native conformation, T cells recognise an antigen only if the antigen is bound and presented by a MHC molecule. Usually this bonding will take place only after appropriate antigen processing, which comprises a proteolytic fragmentation of the
10 protein, so that the peptide fits into the groove of the MHC molecule. Thereby T cells are enabled to also recognise peptides derived from intracellular proteins. T cells can thus theoretically recognise aberrant peptides derived from anywhere in the tumour cell, in the context
15 of MHC molecules on the surface of the tumour cell, and can subsequently be activated to eliminate the tumour cell harbouring the aberrant oncogene.

M.Barinaga, Science, 257, 880-881, 1992 offers a short
20 review of how MHC binds peptides. A more comprehensive explanation of the Technical Background for this Invention may be found in D. Male et al, Advanced Immunology, 1987, J.B.Lippincott Company, Philadelphia. Both references are hereby included in their entirety.

25 The MHC molecules in humans are normally referred to as HLA (human leukocyte antigen) molecules. They are encoded by the HLA region on the human chromosome No 6.

30 The HLA molecules appear as two distinct classes depending on which region of the chromosome codes for them and which T cell subpopulations they interact with and thereby activate primarily. The HLA class I molecules are encoded by the HLA A, B and C subloci and they primarily activate
35 CD8+ cytotoxic T cells. The HLA class II molecules are encoded by the DR, DP and DQ subloci and primarily activate CD4+ T cells.

Normally every individual has six different HLA Class I molecules, usually two alleles from each of the three subgroups A,B and C. However in some cases the number of different HLA Class I molecules is reduced due to occurrence of the same HLA allele twice.

All the gene products are highly polymorphic. Different individuals thus express distinct HLA molecules that differ from those of other individuals. This is the basis for the difficulties in finding HLA matched organ donors in transplantations. The significance of the genetic variation of the HLA molecules in immunobiology is reflected by their role as immune-response genes. Through their peptide binding capacity, the presence or absence of certain HLA molecules governs the capacity of an individual to respond to specific peptide epitopes. As a consequence, HLA molecules determine resistance or susceptibility to disease.

T cells may inhibit the development and growth of cancer by a variety of mechanisms. Cytotoxic T cells, both HLA class I restricted CD8+ and HLA Class II restricted CD4+, may directly kill tumour cells presenting the appropriate tumour antigens. Normally, CD4+ helper T cells are needed for cytotoxic CD8+ T cell responses, but if the appropriate peptide antigen is presented, cytotoxic CD8+ T cells can be activated directly, which results in a quicker, stronger and more efficient response.

While the peptides that are presented by HLA class II molecules are of varying length (12-25 amino acids), the peptides presented by HLA class I molecules must normally be exactly nine amino acid residues long in order to fit into the HLA binding groove. A longer peptide will result in non-binding if it cannot be processed internally by an APC or target cell, such as a cancer cell, before presenting in the HLA groove. Only a very limited number of deviations from this requisition of nine amino acids have been reported, and in those cases the length of the

presented peptide has been either eight or ten amino acid residues long.

5 The explanation for this difference in necessary peptide length for binding, is found in the nature of the peptide binding grooves of HLA class I and II molecules. The peptide binding groove of HLA class I is closed at both ends, whereas the peptide binding groove of HLA class II is open at both ends and therefore allows the binding of
10 longer peptides that protrude from the binding groove.

A requirement for both HLA class I and II binding is that the peptides must contain a binding motif, which normally is different for different HLA groups and subgroups
15 (alleles). A binding motif is characterised by the requirement for specific amino acids in some positions of the peptide so that a narrow fit with the pockets of the HLA binding groove is achieved. Further, it is necessary to avoid some specific amino acids at other positions of
20 the peptide since they cause steric hindrance for binding. The result of this, taken together with the peptide length restriction, is that it is quite unlikely that a peptide binding to one type of HLA class I molecules will also bind to another type. Thus, for example, it may very well
25 be that the peptide binding motif for HLA-A1 and HLA-A2 molecules, which both belong to the class I gender, is as different as the motifs for the HLA-A1 and HLA-B1 molecules.

30 In order to use oncogene derived peptides as vaccines or anti-cancer agents to generate anti tumour CD8+ cytotoxic T cells, it is therefore necessary to investigate the oncogenic antigene in question and identify individual peptides that can bind to the various types of HLA class I
35 molecules. Effective vaccination of an individual can only be achieved if at least one HLA class I allele on an APC can bind a vaccine peptide.

Thus this clearly differs from the situation with HLA class II molecules where it is possible to extend the peptides at both terminals, which makes it possible to design longer peptides that contain epitopes for different types of HLA class II molecules.

Transforming ras genes are the oncogenes most frequently identified in human cancer. It has been established that many of the common cancers such as pancreatic, ovarian, colon rectal, lung and biliary tract carcinomas, result from mutations in ras genes in a high percentage of the patients having such cancers. The protein encoded for by such oncogenes will carry mutations almost exclusively in the positions 12 or 13 or 61 whereas the remaining amino acids in the sequence correspond to the ones found in the p21 ras proto-oncogene protein.

As a consequence synthetic ras peptides can be used as anticancer therapeutical agents or vaccines with the function to trigger the cellular branch of the immune system (T-cells) against cancer cells in patients afflicted with cancers that arise from activated ras oncogenes.

In the present description and claims, the amino acids are represented by their three or one letter abbreviation as known in the art.

Prior art

Scott I. Abrams et al, Eur. J. Immunol. 1996, 26: 435-443 have published results of immunisation of mice with a 4-12 fragment of p21 ras protein having a substitution of Val for Gly at position 12 which resulted in cytotoxic T cell responses (CD8+). These data demonstrate that mutant p21 ras having a Val substitution at position 12 contains a peptide sequence which exhibits specific binding to a murine MHC class I molecule.

The finding that a mouse strain can be immunised is not relevant for the present invention for the following reasons:

5 It is a general observation in mice that strains with different H-2 MHC types recognise different sets of peptides from the same protein, [S.S.Zamvil et al, J.Exp.Med, Vol. 168, (1988), 1181-1186], thus a peptide which elicits an immune response in a mouse of one strain, may not stimulate T cells from another, closely related
10 mouse strain. Also in experimental models, T cells from mice, rats and human beings are known to recognise different, non overlapping epitopes of the same protein. The explanation for this is thought to reside in differences between the species in their antigen
15 processing machinery and peptide binding capabilities of their MHC molecules.

From PCT/NO92/00032 it is known that synthetic peptides spanning the positions 1-25 of p21 ras proteins and
20 fragments having a mutation in positions 12, 13 or 61 can be used to elicit CD4+ T cell immunity against cancer cells harbouring said mutated p21 ras oncogene protein through the administration of such peptides in vaccination or cancer therapy schemes.

25 Although the prior art has identified p21 ras protein fragments that give rise to CD4+ T cell immunity, no previous studies have defined the correct antigens or antigenic sites giving rise to tumour specific cytotoxic
30 CD8+ T cell immunity in humans.

Definition of Problem solved by the Invention.

Thus, although a CD4+ T cell immunity has been achieved and cancer treatment of patients suffering from tumours
35 deriving from p21 ras oncogenes is at present investigated, the activation of the cells capable of killing the tumour cells, namely the cytotoxic T cells, has been difficult to achieve in a sufficient strength.

Further, the cytotoxic T cell activation, as achieved indirectly through a first CD4+ T cell activation, is rather slow. This is a serious problem especially for inoperable patients with a short life time expectation.

5

Therefore there is a need for an anticancer treatment or vaccinating agent, which will establish a strong cytotoxic T cell response against tumours harbouring mutated ras oncogenes in a quick and reliable manner in order to improve the activity of anti-cancer treatment or prophylaxis based on peptides derived from mutated p21 ras proteins.

10

Definition of the Invention

15

It has now according to the present invention been found a group of synthetic peptides which solve the above mentioned problems through the direct activation of cytotoxic CD8+ T cells against tumours harbouring an activated ras oncogene. These peptides are from 8-10 amino acids long and have been shown to be identical to naturally processed epitopes as presented by HLA class I molecules in a human patient suffering from such a tumour.

20

Thus, the peptides according to this invention are characterised in that they

25

a) contains 8-10 amino acids, and encompasses the position 12 and/or 13, or 61 of a p21 ras proto-oncogene protein, and has an amino acid substitution in position 12 or 13 or 61, while the remaining amino acids correspond to the ones found in the same positions of said protein;

30

and

35

b) if the peptide encompasses the positions 12 and 13, they are not both Gly;
and

if the amino acid in position 13 is Gly, the amino acid in position 12 can be any amino acid except Gly;

or

5 if the amino acid in position 12 is Gly, the amino acid in position 13 can be any amino acid except Gly

or

10 if the peptide encompasses the position 61, the amino acid in this position can be any amino acid except Gln;

and

15 c) induces specific cytotoxic T cell (CD8+) responses.

20 The most preferred peptides according to this invention are the peptides consisting of nine amino acids.

Through the peptides of the invention the following advantages are achieved:

- 25 - it is possible to design a stronger anticancer therapy and vaccination;
- the direct activation of the cytotoxic CD8+ T cells results in a quicker establishment of the killer cells necessary to kill the tumour cells;
- 30 - a more direct therapy and prophylaxis directed against the specific genetic alterations presented by neoplastic cells is possible.

According to one aspect of the present invention a pharmaceutical composition is prepared which comprises a peptide of the present invention. The pharmaceutical composition can be used to treat a human patient afflicted with a cancer harbouring a ras oncogene with a mutation in position 12, 13 or 61.

As used in this specification and in the claims the term pharmaceutical composition should not only encompass a composition usable in treatment of cancer patients, but also compositions useful in connection with prophylaxis, i.e. vaccine compositions.

Thus, in another aspect of the present invention, the pharmaceutical composition can be used to vaccinate a human being in order to obtain resistance against cancers arising from ras oncogenes with a mutation in position 12, 13 or 61.

A third aspect of the present invention is the use of the peptides defined above to prepare a pharmaceutical composition for eliciting cytotoxic T cell responses in the treatment or prophylaxis of cancers arising from activated ras oncogenes.

A further aspect of the present invention is a method for the treatment of a human patient afflicted with cancer which comprises administering at least one peptide of the invention in an amount effective to elicit a cytotoxic (CD8+) T cell response.

Yet another aspect of the invention is a method for the vaccination of a human being in order to obtain resistance against cancers arising from activated ras oncogenes, which comprises administering at least one peptide of the invention, in an amount effective to elicit a cytotoxic T cell response.

In another aspect of the present invention the peptides of the invention are administered in a pharmaceutical composition or in the methods for the treatment or prophylaxis described above as a mixture of peptides. The mixture may either be:

(a) a mixture of peptides having different mutations in one position, i.e. position 12 or position 13 or position

61.
or
(b) a mixture of peptides having the same mutation, but
suitable to fit different HLA alleles
5 or
(c) a mixture of both mixtures (a) and (b)
or
(d) a mixture of several mixtures (a)
or
10 (e) a mixture of several mixtures (b)
or
(f) a mixture of several mixtures (a) and
several mixtures (b).
- 15 Alternatively the peptides in the mixtures may be
covalently linked with each other to form larger
polypeptides or even cyclic polypeptides.

20 The amino acids chosen in position 12, 13 or 61 in the
above mentioned mixtures would be the most commonly found
mutations in a specific cancer. Such mixture or mixtures
would then be suitable for the treatment of a patient
afflicted with said cancer or for the prophylaxis of a
person belonging to a risk group for said cancer.

25 In the prophylactic treatment of persons not belonging to
any specific risk group, but which may still be in the
danger of becoming ill from a cancer harbouring mutated
ras oncogene, the administration of a mixture as defined
30 in abstract (f) is considered useful.

In this manner it is possible to adopt the present
invention to the different aspects mention above.

35 It is a purpose of the present invention to produce a
cancer therapy or vaccine for cancers harbouring mutated
ras oncogenes, by inducing T cell immunity either in
vitro, ex vivo or in vivo with the peptides according to

the present invention.

Another purpose of the present invention is to design an anti-cancer treatment or prophylaxis specifically adapted to a human individual in need of such treatment or prophylaxis, which comprises administering at least one peptide according to this invention. The administration may take place one or several times as suitable to establish and/or maintain the wanted cytotoxic T cell immunity.

It is further anticipated that the power of an anticancer vaccine or peptide drug as disclosed in the above mentioned PCT/NO92/00032 application, can be enhanced if the peptides of this invention were included. This is based on the assumption that if both specific CD8+ T cells (cytotoxic T cells) and specific CD4+ T cell responses may be induced at the same time, it will lead to an even stronger T cell immunity. Thus in another embodiment of the present invention peptides of the present invention are administered together with, either simultaneously or in optional sequence, the peptides disclosed in PCT/NO92/00032.

25

Embodiments

The most preferred peptides according to the invention are those which carry the amino acids substitutions most commonly found in human cancers arising from mutated ras oncogenes. In position 12 of p21 ras proteins the most commonly found mutations are Asp, Val, Arg, Cys, Ala and Ser. In position 13 the most commonly found mutations are Asp and Val. In position 61 the most commonly found mutations are Arg, His, Lys and Leu.

35

One group of preferred peptides according to this invention are the following peptides, wherein X_1 represents position 12 in the p21 ras protein and can be any amino

acid except Gly:

X_1 GVGKSALT,
AX₁GVGKSAL,
GAX₁GVGKSA,
5 VVAX₁GVGKS,
VVGAX₁GVGK,
VVVGAX₁GVG,
LVVGAX₁GV,
KLVVGAX₁G,
10 YKLVVGAX₁

The most preferred peptides of the above group are those wherein X_1 is Asp, Val, Arg, Ala, Cys or Ser.

15 A further group of peptides of this invention are the following, wherein X_1 represents position 12 in a p21 ras protein and can be any amino acid except Gly:

X_1 GVGKSAL
AX₁GVGKSA,
20 GAX₁GVGKS,
VVGAX₁GVGK,
VVGAX₁GVG,
VVVGAX₁GV,
LVVGAX₁G,
25 KLVVGAX₁

The most preferred peptides of the above group are those wherein X_1 is Asp, Val, Arg, Ala, Cys or Ser.

30 A further group of peptides of this invention are the following, wherein X_1 represents position 12 of a p21 ras protein and can be any amino acid except Gly:

X_1 GVGKSALTI,
AX₁GVGKSALT,
35 GAX₁GVGKSAL,
VVGAX₁GVGKSA,
VVGAX₁GVGKS,
VVVGAX₁GVGK,

LVVVGAX₁GVG,
KLVVVGAX₁GV,
YKLVVVGAX₁G,
EYKLVVVGAX₁

- 5 The most preferred peptides of the above group are those wherein X₁ is Asp, Val, Arg, Ala, Cys or Ser.

A second group of especially preferred peptides according to this invention are the following wherein X₂ represents position 13 of the p21 ras protein and can be any amino acid except Gly:

10 X₂VGKSALTI,
GX₂VGKSALT,
AGX₂VGKSAL,
15 GAGX₂VGKSA,
VGAGX₂VGKS,
VVGAGX₂VGK,
VVVGAGX₂VG,
LVVVGAGX₂V,
20 KLVVVGAGX₂

The most preferred peptides of the above group are those wherein X₂ is Asp or Val.

A further group of peptides of the invention are the following wherein X₂ represents position 13 of the p21 ras protein and can be any amino acid except Gly:

25 X₂VGKSALT,
GX₂VGKSAL,
AGX₂VGKSA,
30 GAGX₂VGKS,
VGAGX₂VGK,
VVGAGX₂VG,
VVVGAGX₂V,
LVVVGAGX₂

- 35 The most preferred peptides of the above group are those wherein X₂ is Asp or Val.

A further group of peptides of the invention are the

following wherein X_2 represents position 13 of the p21 ras protein and can be any amino acid except Gly:

X_2 VGKSALTIQ

G X_2 VGKSALTI

5 AG X_2 VGKSALT

GAG X_2 VGKSAL

VGAG X_2 VGKSA

VVGAG X_2 VGKS

VVGAG X_2 VGK

10 LVVGAG X_2 VG

KLVGAG X_2 V

YKLVVGAG X_2

The most preferred peptides of the above group are those wherein X_2 is Asp or Val.

15

A third group of preferred peptides according to this invention are the following wherein X_3 represents position 61 of the p21 ras protein and can be any amino acid except Gln:

20 X_3 EEYSAMRD

G X_3 EEYSAMR

AG X_3 EEYSAM

TAG X_3 EEYSA

DTAG X_3 EEYS

25 LDTAG X_3 EEY

ILDTAG X_3 EE

DILDTAG X_3 E

LDILDTAG X_3

The most preferred peptides of the above group are those wherein X_3 is Arg, Lys, His or Leu.

30

A further group of peptides of the invention are the following wherein X_3 represents position 61 of the p21 ras protein and can be any amino acid except Gln:

35 X_3 EEYSAMR,

G X_3 EEYSAM,

AG X_3 EEYSA,

TAG X_3 EEYS,

DTAGX₃EEY,
LDTAGX₃EE,
ILDTAGX₃E,
DILDTAGX₃

- 5 The most preferred peptides of the above group are those wherein X₃ is Arg, Lys, His or Leu.

A further group of peptides of the invention are the following wherein X₃ represents position 61 of the p21 ras protein and can be any amino acid except Gln:

10 X₃EEYSAMRDQ,
GX₃EEYSAMRD,
AGX₃EEYSAMR,
TAGX₃EEYSAM,
15 DTAGX₃EEYSA,
LDTAGX₃EEYS,
ILDTAGX₃EEY,
DILDTAGX₃EE,
LDILDLAGX₃E,
20 LLDILDLAGX₃

The most preferred peptides of the above group are those wherein X₃ is Arg, Lys, His or Leu.

- 25 As appears from the listing of peptides above, the peptides according to the present invention may be symmetrical or unsymmetrical around each of the positions where the mutations are found in the oncogene proteins.

- 30 It is considered that the peptides may be administered together, either simultaneously or separately, with compounds such as cytokines and/or growth factors, i.e. interleukin-2 (IL-2), interleukin-12 (IL-12), granulocyte macrophage colony stimulating factor (GM-CSF) or the like
35 in order to strengthen the immune response as known in the art.

The peptides according to the present invention can be

used in a vaccine or a therapeutical composition either alone or in combination with other materials, such as for instance in the form of a lipopeptide conjugate which as known in the art can induce high-affinity cytotoxic T cells (K. Deres, Nature, Vol.342, (nov.1989)).

The peptides according to the present invention may be useful to include in either a synthetic peptide or recombinant fragment based vaccine.

10

The peptides of the present invention are particularly suited for use in a vaccine capable of safely eliciting cytotoxic CD8+ T cell immunity:

- 15 (1) the peptides are synthetically produced and therefore do not include transforming cancer genes or other sites or materials which might produce deleterious effects,
- 20 (2) the peptides may be used alone to induce cytotoxic T cellular immunity,
- (3) the peptides may be targeted for cytotoxic T cell responses without the side effects of other unwanted responses.

25

The peptides according to the present invention can be included in pharmaceutical compositions alone or together with usual pharmaceutically acceptable additives, adjuvants, diluents, stabilisers, carriers or the like as known in the art.

30

The peptides of the invention can be administered in an amount in the range of 1mg - 1g to an average human patient or individual to be vaccinated. It is more preferred to use a smaller dose in the range of 1mg - 10mg for each administration.

35

A person skilled in the art will find other possible modes of using the peptides of this invention, and these are meant to be encompassed by the present claim.

A cancer therapy according to the present invention may be administered both in vivo, ex vivo or in vitro having as the main goal the raising of specific cytotoxic T cell lines or clones against the gene product of the oncogene responsible for the cancer type with which the patient is afflicted.

The peptides according to this invention may be produced by conventional processes as known in the art, and this is elucidated in the description of the synthesis below.

The invention is further described in the claims.

BIOLOGICAL EXPERIMENTS

In order for a cancer vaccine and methods for specific cancer therapy based on specific T cell immunity to be effective, three conditions must be met:

1. The peptide used must correspond to the processed p21 ras oncogene protein fragment as presented by a HLA Class I molecule on the cancer cell or on professional antigen presenting cells,

2. The peptides used must be bound to a HLA Class I molecule in an immunogenic form, and

3. Cytotoxic T-cells (CD8+) capable of recognising and responding to the HLA Class I/peptide complex must be present in the circulation of the human being.

It has been established that all these conditions are met for the peptides according to the present invention. The peptides according to the present invention give rise to specific cytotoxic T cell immune responses in vitro. HLA Class I molecules capable of binding the peptides were determined. It has been established that the synthetic peptides according to this invention correspond to the processed oncogene protein fragments. This is exemplified

with synthetic p21 ras peptide fragments having a mutation in position 12. The specificity of cytotoxic T cells induced in vivo by ras peptide vaccination was determined with the peptides of the invention. This is a clear indication that the cancer patient's T cells had been activated by the identical peptide fragments in vivo.

Description of the Figures

Figure 1 shows that a CD8⁺ cytotoxic T cell clone (CTL 69-30) which was obtained from peripheral blood from a pancreatic carcinoma patient after 12Val mutant ras peptide vaccination, can recognize and kill different tumor cell lines expressing 12Val mutated p21 ras. The cytotoxic T cell clone was obtained after cloning of T-cell blasts present in peripheral blood mononuclear cells (PBMC) from a pancreatic carcinoma patient after position 12 Val mutant ras peptide vaccination. The peptide vaccination protocol included several infusions of large amounts of peptide-loaded autologous professional antigen-presenting cells (APC). Cloning of T cells was performed by plating responding T cell blasts at 5 blasts per well onto Terasaki plates. Each well contained 2×10^4 autologous, irradiated (30 Gy) PBMC as feeder cells, and the cells were propagated with the 12Val peptide at 25 mM and 5 U/ml recombinant interleukin-2 (rIL-2) (Amersham, Aylesbury, UK) in a total volume of 20 mL. After 9 days T cell clones were transferred onto flat-bottomed 96-well plates (Costar, Cambridge, MA) with 1 mg/ml phytohemagglutinin (PHA, Wellcome, Dartford, UK), 5 U/ml rIL-2 and allogeneic irradiated (30 Gy) PBMC (2×10^5) per well as feeder cells. Growing clones were further expanded in 24-well plates with PHA / rIL-2 and 1×10^6 allogeneic, irradiated PBMC as feeder cells and screened for peptide specificity after 4 to 7 days. T cell clone 69-30 was selected for further characterisation. It was found that it expresses the cell-surface phenotype CD3, CD8 and TcR ab. When tested at different effector to target ratios, it was found that CTL 69-30 exhibits lysis of autologous tumour cell targets, which indicates that it is directed against a

tumour derived antigen, such as mutant ras.

In order to verify that the antigen recognised is associated with mutant ras, and to identify the HLA class I molecule presenting the putative mutant ras peptide to the cytotoxic T cell clone, different 12Val p21 ras expressing tumour cell lines carrying one or more HLA class I molecules in common with those of the patient, were used as target cells in cytotoxicity assays. Target cells were labelled with ^3H -thymidine (9.25×10^4 Bq/mL) over night, washed once and plated 5000 cells per well in 96 well plates. T cells were added at different effector to target ratios and the plates were incubated for 4 hours at 37°C and then harvested before counting in a liquid scintillation counter (Packard Topcount). Data represent percent specific lysis of ^3H -thymidine labelled target cells in a 4h assay at different effector/target ratios. Values are expressed as the mean of triplicate cultures $\pm$ SD. T cell clone 69-30 demonstrated lysis of the bladder carcinoma cell line T24 (12Val⁺, HLA-A1⁺, B35⁺) and the melanoma cell line FMEX (12Val⁺, HLA-A2⁺, B35⁺), but not of the colon carcinoma cell line SW 480 (12Val⁺, HLA-A2⁺, B8⁺). The autologous EBV-B cells (12Val⁻, HLA-A1⁺, A2⁺, B8⁺, B35⁺) and the natural killer target K562 used as controls, were not lysed. These results suggest that T cell clone 69-30 recognises an endogenously-processed 12Val epitope in the context of HLA-B35.

Figure 2 further demonstrates the HLA class I restriction of T cell clone 69-30 by blocking experiments. The results show that the cytolytic effect of T cell clone 69-30 on autologous pancreatic carcinoma cells (CPE) could be blocked by a panreactive HLA class I mAb (W6/32), but remained unaltered in the presence of monoclonal antibodies directed against HLA class II DR, DQ and DP antigens. Taken together with the results obtained with the different 12Val expressing tumour cell lines, these data demonstrate HLA class I restriction and indicate that HLA-B35 is the restricting molecule of T

cell clone 69-30. Specific lysis of CPE-targets was HLA class I restricted as demonstrated by experiments involving monoclonal antibodies directed against HLA class I (W6/32) and class II (B8/11, SPV-L3 and B7/21) antigens. The
5 cytotoxic T cell clone activity against the autologous tumour cell line was evaluated using monoclonal antibodies directed against HLA class I and class II molecules at a final concentration of 10 mg/ml. Assays were set up in triplicate in 96 well plates and the target cells were
10 preincubated for 30 minutes at 37°C before addition of T cells. Results obtained with an effector/target ratio of 10/1 are shown. Data represent percent specific lysis against ³H-thymidine labelled CPE targets and the various mAbs in a 4h assay, with activity expressed as the mean $\pm$ SD
15 of triplicate cultures.

Figure 3 shows the fine specificity of T cell clone 69-30 in peptide pulsing experiments. To identify the mutant ras peptide actually being recognised by T cell clone 69-30,
20 the panel of nonamer peptides; peptide 10-18, spanning positions 4 to 20 of p21 ras containing the Val substitution at position 12, was tested. Only peptide 15 was capable of stimulating T cell clone 69-30 activity in these experiments. ³H-thymidine labelled, mild acid eluted
25 autologous EBV-B cells were plated 2500 cells per well in 96 well plates and pulsed with the peptides at a concentration of 1 mM together with b2-microglobulin (2.5 mg/mL) in a 5% CO₂ incubator at 37°C before addition of the T cells. Assays were set up in triplicate in 96 well plates and incubated for 4 hours with
30 an effector to target ratio of 5 to 1. The specificity of cytotoxic T cell clone recognition for the appropriate mutant peptide was illustrated by the absence of lysis observed with the peptide expressing normal ras sequence.
35 Controls included T cell clone cultured alone, with APC in the absence of peptides or with an irrelevant melanoma associated peptide MART-1/Melan-A peptide. Data are given as mean of triplicate cultures.

Figure 4 shows the sensitivity of the T cell clone 69-30 to peptide 15. The data show that an anti-ras cytotoxic T cell activity was detectable over a range of several log units, with maximal lysis at 1×10^{-6} M and half maximal response at 1×10^{-9} M peptide concentration. This was examined in a dose-response experiment using peptide sensitised EBV-B cells as target cells. The target cells were pulsed with peptide 15 as described in Figure 3, with the exception that the peptides were added at different concentrations before the addition of T cells. Controls included target cells alone and target cells pulsed with the irrelevant melanoma associated peptide Melan-A/Mart-1. Data are expressed as the mean of triplicate cultures $\pm$ SD.

Figure 5 shows the fine specificity of T cell clone 42-33 in peptide pulsing experiments. T cell clone 42-33 was also obtained from a vaccinated patient. Of the panel of nonamer peptides; peptide 10-18, only peptide 18 was capable of stimulating T cell clone 42-33. In the experiments the TAP deficient T2 cell line was used as antigen presenting cells. This cell line expresses only small amounts of HLA-A2 antigen, but increased levels of HLA class I antigens at the cell surface can be induced by addition of β 2-microglobulin. 3 H-labelled target cells were incubated with the different test peptides and control peptides at a concentration of 1 mM together with β 2-microglobulin (2.5 mg/mL) for one hour at 37°C. After peptide pulsing, the target cells were washed extensively, counted and plated 2500 cells per well in 96 well plates before addition of the T cells. The plates were incubated for 4 hours at 37°C in 5% CO₂ before harvesting. Controls included T cell clone cultured alone or with target cells in the absence of peptides. Assays were set up in triplicate in 96 well plates with an effector to target ratio of 20 to 1.

35

Figure 6 shows the specificity of the 12-Cys-p21 ras specific CD8+ CTL EG2.4 that recognize and kill autologous EBV cells pulsed with peptide (seq id no) 23 and 24. The CTL

was obtained after cloning of T cell blasts present in PBMC from a pancreatic carcinoma patient after mutant ras peptide vaccination. The peptide vaccination protocol consisted of 6 intradermal injections of a mixture of mutant ras peptides in combination with granulocyte-macrophage colony stimulating factor (GM-CSF). Cloning of T cells was performed as described above. ^{51}Cr + labelled target cells were plated in 96-well plates (Costar) and incubated with synthetic peptides and b2-microglobulin for 1 hour. Then the cells were washed before adding the T cells. The plates were incubated for 4 hours at 37°C in 5% CO_2 before harvesting. Peptide 23 and 24 were capable of stimulating TLC-EG2.4 whereas the other nonamers were not. Assays were set up in triplicate with an effector to target ratio of 25 to 1.

Figure 7 shows the specificity of the 12-Cys p21 ras specific CD8+ CTL EG2.8. This CTL recognize and kill autologous EBV cells pulsed with peptide (seq id no) 23 and 24. Generation of the CTL was done as outlined above.

Figure 8 shows the sensitivity of the TLC EG2.4 to exogenous peptide. This was examined in a dose-response experiment using ^{51}Cr + labelled, peptide sensitized EBV-B cells as target cells. The target cells were pulsed with peptide 23 and 24 separately as described in figure 6, with the exception that the peptides were added at different concentrations before the addition of T cells. Anti-ras CTL activity was detectable over a several log range for peptide 23, with maximal lysis at 1×10^{-5} M and halfmaximal response at 1×10^{-7} M peptide concentration, whereas peptide 24 could not stimulate the CTL at comparable peptide concentrations. Assays were set up in triplicate cultures with an effector to target ratio of 10 to 1. Data are expressed as the mean of triplicate cultures.

Figure 9 shows the sensitivity of TLC EG2.8 to exogenous peptide. This was examined as described in figure 8. Anti-ras CTL activity was demonstrable over a several log range

for peptide 23, but was not detectable for peptide 24 at comparable peptide concentrations. Assays were set up in triplicate cultures with an effector to target ratio of 10 to 1. Data are given as expressed in figure 8.

5

Synthesis

The peptides were synthesised by using continuous flow solid phase peptide synthesis (9050 PepSynthesizer, MilliGen or Novasyn Crystal peptide synthesiser, Novabiochem). N-a-Fmoc-amino acids with appropriate side chain protection (Ser(tBu), Thr(tBu), Tyr(tBu), Lys(Boc), His(Trt), Arg(Pmc), Cys(Trt), Asp(O-tBu), Glu(O-tBu)) were used. The Fmoc-amino acids were activated by TBTU prior to coupling. 20% piperidine in DMF was used for selective removal of Fmoc after each coupling. Detachment from the resin and final removal of side chain protection was performed by 95% TFA (aq.). The peptides were purified and analysed by reversed phase (C18) HPLC (Shimadzu LC8A). The identity of the peptides was confirmed by using electro-spray mass spectroscopy (Finnigan mat SSQ710).

15

The peptides which were synthesised by this method are listed in the Sequence ID listing.

25

30

35

Claims

1. A peptide characterised in that it

5

a) contains 8-10 amino acids, and encompasses the position 12 and/or 13, or 61 of a p21 ras proto-oncogene protein, and has an amino acid substitution in position 12 or 13 or 61, while the remaining

10 amino acids correspond to the ones found in the same positions of said protein;

and

15

b) if the peptide encompasses the positions 12 and 13, they are not both Gly;

and

if the amino acid in position 13 is Gly, the amino acid in position 12 can be any amino acid

20 except Gly;

or

if the amino acid in position 12 is Gly, the amino acid in position 13 can be any amino acid

25 except Gly

25

or

if the peptide encompasses the position 61, the amino acid in this position can be any amino acid

30 except Gln;

30

and

c) induces specific cytotoxic T cell (CD8+) responses.

35

2. A peptide according to claim 1 characterised in that it consists of 9 amino acids.

3. A Peptide according to claim 2 characterised in that it is selected from the following group:

X₁GVGKSALT

AX₁GVGKSAL

5 GAX₁GVGKSA

VGAX₁GVGKS

VVGAX₁GVGK

VVVGAX₁GVG

LVVVGAX₁GV

10 KLVVVGAX₁G

YKLVVVGAX₁

wherein X₁ can be any amino acid except Gly, but X₁ is most preferred Asp, Val, Arg, Ala, Cys or Ser.

15 4. A Peptide according to claim 2 characterised in that it is selected from the group consisting of:

X₂VGKSALTI

GX₂VGKSALT

AGX₂VGKSAL

20 GAGX₂VGKSA

VGAGX₂VGKS

VVGAGX₂VGK

VVVGAGX₂VG

LVVVGAGX₂V

25 KLVVVGAGX₂

X₂ can be any amino acid except Gly, but X₂ is most preferred Asp or Val.

30

35

5. A Peptide according to claim 2 characterised in that it is selected from the group consisting of:

X₃EEYSAMRD

GX₃EEYSAMR

5 AGX₃EEYSAM

TAGX₃EEYSA

DTAGX₃EEYS

LDTAGX₃EEY

ILDTAGX₃EE

10 DILDTAGX₃E

LDILDTAGX₃

X₃ can be any amino acid except Gln, but X₃ is most preferred Arg, Lys, His or Leu.

15 6. A pharmaceutical composition comprising at least one peptide according to any of the claims 1-5 and a pharmaceutically acceptable carrier or diluent.

20 7. A pharmaceutical composition according to claim 6 for the treatment of a human patient afflicted with a cancer associated with activated ras oncogenes.

25 8. A pharmaceutical composition according to claim 7 for the treatment of a patient afflicted with any of the following: pancreatic cancer, colo-rectal cancer, lung cancer, malignant melanoma, ovarian cancer, and biliary tract carcinomas.

30 9. A pharmaceutical composition according to claim 6 for the prophylactic treatment of a human being, to obtain resistance against a cancer associated with activated ras oncogenes.

35 10. A pharmaceutical composition according to claim 9 for the prophylactic treatment of a human being to obtain resistance against pancreatic cancer, colo-rectal cancer, lung cancer, malignant melanoma, ovarian cancer, and biliary tract carcinomas.

11. A pharmaceutical composition comprising a combination of at least one peptide according to claims 1-5 and at least one peptide according to PCT/NO92/00032.

5 12. Pharmaceutical composition comprising a mixture of peptides according to the claims 1-5.

13. Use of a peptide according to any of the claims 1-5 for the preparation of a pharmaceutical composition for
10 eliciting specific cytotoxic (CD8+) T-cell responses in the treatment or prophylaxis of cancers associated with activated ras oncogenes.

14. Method for the treatment of a patient afflicted with
15 cancer associated with p21 ras oncogenes, by eliciting specific cytotoxic (CD8+) T-cell responses through stimulating in vivo, ex vivo or in vitro with a peptide according to the claims 1-5.

20 15. Method for the vaccination of a human being in order to obtain resistance against cancers associated with activated ras oncogenes, by eliciting specific cytotoxic (CD8+) T-cell responses through stimulating in vivo, ex vivo or in vitro with a peptide according to the claims 1-5.


25

30

35


1/9

% specific lysis




2/9

Mab directed against




3/9

peptide (seq id no)




4/9

% specific lysis

 μM peptide 15


5/9

peptide (seq id no)




6/9

TLC EG2.4
a 12-Cys-p21 ras specific CD8+ T Cell clone




7/9

TLC EG2.8
a 12-Cys-p21 ras specific CD8+ T Cell clone



8/9

TLC EG2.4
Dose - Response to exogenous peptides



EBV + seq id no 23

—★—


EBV + seq id no 24

—◆—

9/9

TLC EG2.8

Dose - Response to exogenous peptide



EBV + seq id no 23

—★—

EBV + seq id no 24

—◆—

Sequence identity list

SEQUENCE LISTING

COMMON FOR ALL THE FOLLOWING SEQUENCES.

SEQUENCE TYPE: Peptide

SEQ ID NO: 1

(12 non Gly)

SEQUENCE LENGTH: 9 amino acids

Asp Gly Val Gly Lys Ser Ala Leu Thr

1

5

SEQ ID NO: 2

SEQUENCE LENGTH: 9 amino acids

Ala Asp Gly Val Gly Lys Ser Ala Leu

1

5

SEQ ID NO: 3

SEQUENCE LENGTH: 9 amino acids

Gly Ala Asp Gly Val Gly Lys Ser Ala

1

5

SEQ ID NO: 4

SEQUENCE LENGTH: 9 amino acids

Val Gly Ala Asp Gly Val Gly Lys Ser

1

5

SEQ ID NO: 5

SEQUENCE LENGTH: 9 amino acids

Val Val Gly Ala Asp Gly Val Gly Lys

1

5

SEQ ID NO: 6

SEQUENCE LENGTH: 9 amino acids

Val Val Val Gly Ala Asp Gly Val Gly

1

5

SEQ ID NO: 7

SEQUENCE LENGTH: 9 amino acids

Leu Val Val Val Gly Ala Asp Gly Val

1

5

SEQ ID NO: 8

SEQUENCE LENGTH: 9 amino acids

Lys Leu Val Val Val Gly Ala Asp Gly

1

5

SEQ ID NO: 9

SEQUENCE LENGTH: 9 amino acids

Tyr Lys Leu Val Val Val Gly Ala Asp

1

5

SEQ ID NO: 10

SEQUENCE LENGTH: 9 amino acids

Val Gly Val Gly Lys Ser Ala Leu Thr

1

5

SEQ ID NO: 11

SEQUENCE LENGTH: 9 amino acids

Ala Val Gly Val Gly Lys Ser Ala Leu

1

5

SEQ ID NO: 12

SEQUENCE LENGTH: 9 amino acids

Gly Ala Val Gly Val Gly Lys Ser Ala

1

5

SEQ ID NO: 13

SEQUENCE LENGTH: 9 amino acids

Val Gly Ala Val Gly Val Gly Lys Ser

1

5

SEQ ID NO: 14

SEQUENCE LENGTH: 9 amino acids

Val Val Gly Ala Val Gly Val Gly Lys

1

5

SEQ ID NO: 15

SEQUENCE LENGTH: 9 amino acids

Val Val Val Gly Ala Val Gly Val Gly

1

5

SEQ ID NO: 16

SEQUENCE LENGTH: 9 amino acids

Leu Val Val Val Gly Ala Val Gly Val

1

5

SEQ ID NO: 17

SEQUENCE LENGTH: 9 amino acids

Lys Leu Val Val Val Gly Ala Val Gly

1

5

SEQ ID NO: 18

SEQUENCE LENGTH: 9 amino acids

Tyr Lys Leu Val Val Gly Ala Val

1 5

SEQ ID NO: 19

SEQUENCE LENGTH: 9 amino acids

Cys Gly Val Gly Lys Ser Ala Leu Thr

1 5

SEQ ID NO: 20

SEQUENCE LENGTH: 9 amino acids

Ala Cys Gly Val Gly Lys Ser Ala Leu

1 5

SEQ ID NO: 21

SEQUENCE LENGTH: 9 amino acids

Gly Ala Cys Gly Val Gly Lys Ser Ala

1 5

SEQ ID NO: 22

SEQUENCE LENGTH: 9 amino acids

Val Gly Ala Cys Gly Val Gly Lys Ser

1 5

SEQ ID NO: 23

SEQUENCE LENGTH: 9 amino acids

Val Val Gly Ala Cys Gly Val Gly Lys

1 5

SEQ ID NO: 24

SEQUENCE LENGTH: 9 amino acids

Val Val Val Gly Ala Cys Gly Val Gly

1 5

SEQ ID NO: 25

SEQUENCE LENGTH: 9 amino acids

Leu Val Val Val Gly Ala Cys Gly Val

1 5

SEQ ID NO: 26

SEQUENCE LENGTH: 9 amino acids

Lys Leu Val Val Val Gly Ala Cys Gly

1 5

SEQ ID NO: 27

SEQUENCE LENGTH: 9 amino acids

Tyr Lys Leu Val Val Val Gly Ala Cys

1 5

SEQ ID NO: 28

SEQUENCE LENGTH: 10 amino acids

Lys Leu Val Val Val Gly Ala Asp Gly Val

1 5 10

SEQ ID NO: 29

SEQUENCE LENGTH: 10 amino acids

Val Gly Ala Val Gly Val Gly Lys Ser Ala

1 5 10

SEQ ID NO: 30

SEQUENCE LENGTH: 10 amino acids

Val Val Gly Ala Val Gly Val Gly Lys Ser

1 5 10

SEQ ID NO: 31

SEQUENCE LENGTH: 10 amino acids

Gly Ala Arg Gly Val Gly Lys Ser Ala Leu

1 5 10

SEQ ID NO: 32

SEQUENCE LENGTH: 10 amino acids

Leu Val Val Val Gly Ala Arg Gly Val Gly

1 5 10

SEQ ID NO: 33

SEQUENCE LENGTH: 10 amino acids

Val Val Gly Ala Ala Gly Val Gly Lys Ser

1 5 10

SEQ ID NO: 34

SEQUENCE LENGTH: 10 amino acids

Leu Val Val Val Gly Ala Ala Gly Val Gly

1 5 10

SEQ ID NO: 35

SEQUENCE LENGTH: 8 amino acids

Val Gly Ala Val Gly Val Gly Lys

1 5

SEQ ID NO: 36

SEQUENCE LENGTH: 8 amino acids

Lys Leu Val Val Val Gly Ala Val

1 5

SEQ ID NO: 37

SEQUENCE LENGTH: 8 amino acids

Lys Leu Val Val Val Gly Ala Asp

1

5

SEQ ID NO: 38

SEQUENCE LENGTH: 9 amino acids

Asp Val Gly Lys Ser Ala Leu Thr Ile

1

5

(13 non Gly)

SEQ ID NO: 39

SEQUENCE LENGTH: 9 amino acids

Gly Asp Val Gly Lys Ser Ala Leu Thr

1

5

SEQ ID NO: 40

SEQUENCE LENGTH: 9 amino acids

Ala Gly Asp Val Gly Lys Ser Ala Leu

1

5

SEQ ID NO: 41

SEQUENCE LENGTH: 9 amino acids

Gly Ala Gly Asp Val Gly Lys Ser Ala

1

5

SEQ ID NO: 42

SEQUENCE LENGTH: 9 amino acids

Val Gly Ala Gly Asp Val Gly Lys Ser

1

5

SEQ ID NO: 43

SEQUENCE LENGTH: 9 amino acids

Val Val Gly Ala Gly Asp Val Gly Lys

1

5

SEQ ID NO: 44

SEQUENCE LENGTH: 9 amino acids

Val Val Val Gly Ala Gly Asp Val Gly

1

5

SEQ ID NO: 45

SEQUENCE LENGTH: 9 amino acids

Leu Val Val Val Gly Ala Gly Asp Val

1

5

SEQ ID NO: 46

SEQUENCE LENGTH: 9 amino acids

Lys Leu Val Val Val Gly Ala Gly Asp

1

5

SEQ ID NO: 47

SEQUENCE LENGTH: 10 amino acids

Asp Val Gly Lys Ser Ala Leu Thr Ile Gln

1 5 10

SEQ ID NO: 48

SEQUENCE LENGTH: 10 amino acids

Gly Asp Val Gly Lys Ser Ala Leu Thr Ile

1 5 10

SEQ ID NO: 49

SEQUENCE LENGTH: 10 amino acids

Ala Gly Asp Val Gly Lys Ser Ala Leu Thr

1 5 10

SEQ ID NO: 50

SEQUENCE LENGTH: 10 amino acids

Gly Ala Gly Asp Val Gly Lys Ser Ala Leu

1 5 10

SEQ ID NO: 51

SEQUENCE LENGTH: 10 amino acids

Val Gly Ala Gly Asp Val Gly Lys Ser Ala

1 5 10

SEQ ID NO: 52

SEQUENCE LENGTH: 10 amino acids

Val Val Gly Ala Gly Asp Val Gly Lys Ser

1 5 10

SEQ ID NO: 53

SEQUENCE LENGTH: 10 amino acids

Val Val Val Gly Ala Gly Asp Val Gly Lys

1 5 10

SEQ ID NO: 54

SEQUENCE LENGTH: 10 amino acids

Leu Val Val Val Gly Ala Gly Asp Val Gly

1 5 10

SEQ ID NO: 55

SEQUENCE LENGTH: 10 amino acids

Lys Leu Val Val Val Gly Ala Gly Asp Val

1 5 10

SEQ ID NO: 56

SEQUENCE LENGTH: 10 amino acids

Tyr Lys Leu Val Val Val Gly Ala Gly Asp

1 5 10

SEQ ID NO: 57

SEQUENCE LENGTH: 8 amino acids

Asp Val Gly Lys Ser Ala Leu Thr

1 5

SEQ ID NO: 58

SEQUENCE LENGTH: 8 amino acids

Gly Asp Val Gly Lys Ser Ala Leu

1 5

SEQ ID NO: 59

SEQUENCE LENGTH: 8 amino acids

Ala Gly Asp Val Gly Lys Ser Ala

1 5

SEQ ID NO: 60

SEQUENCE LENGTH: 8 amino acids

Gly Ala Gly Asp Val Gly Lys Ser

1 5

SEQ ID NO: 61

SEQUENCE LENGTH: 8 amino acids

Val Gly Ala Gly Asp Val Gly Lys

1 5

SEQ ID NO: 63

SEQUENCE LENGTH: 8 amino acids

Val Val Gly Ala Gly Asp Val Gly

1 5

SEQ ID NO: 64

SEQUENCE LENGTH: 8 amino acids

Val Val Val Gly Ala Gly Asp Val

1 5

SEQ ID NO: 65

SEQUENCE LENGTH: 8 amino acids

LysVal Val Val Gly Ala Gly Asp

1 5

SEQ ID NO: 66

SEQUENCE LENGTH: 9 amino acids

Leu Glu Glu Tyr Ser Ala Met Arg Asp

1 5

(61 non Gln)

SEQ ID NO: 67

SEQUENCE LENGTH: 9 amino acids

Gly Leu Glu Glu Tyr Ser Ala Met Arg

1 5

SEQ ID NO: 68

SEQUENCE LENGTH: 9 amino acids

Ala Gly Leu Glu Glu Tyr Ser Ala Met

1 5

SEQ ID NO: 69

SEQUENCE LENGTH: 9 amino acids

Thr Ala Gly Leu Glu Glu Tyr Ser Ala

1 5

SEQ ID NO: 70

SEQUENCE LENGTH: 9 amino acids

Asp Thr Ala Gly Leu Glu Glu Tyr Ser

1 5

SEQ ID NO: 71

SEQUENCE LENGTH: 9 amino acids

Leu Asp Thr Ala Gly Leu Glu Glu Tyr

1 5

SEQ ID NO: 72

SEQUENCE LENGTH: 9 amino acids

Ile Leu Asp Thr Ala Gly Leu Glu Glu

1 5

SEQ ID NO: 73

SEQUENCE LENGTH: 9 amino acids

Asp Ile Leu Asp Thr Ala Gly Leu Glu

1 5

SEQ ID NO: 74

SEQUENCE LENGTH: 9 amino acids

Leu Asp Ile Leu Asp Thr Ala Gly Leu

1 5

SEQ ID NO: 75

SEQUENCE LENGTH: 10 amino acids

Leu Leu Asp Ile Leu Asp Thr Ala Gly Leu

1 5 10

SEQ ID NO: 76

SEQUENCE LENGTH: 8 amino acids

Asp Ile Leu Asp Thr Ala Gly Leu

1 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NO 98/00252

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/82, C07K 7/06, A61K 38/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REG, CAPLUS, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9740156 A1 (THE GOVERNMENT OF THE UNITED STATES OF AMERICA), 30 October 1997 (30.10.97) --	1-13
P,X	Int J. Cancer, Volume 72, 1997, Marianne K. Gjertsen et al, "Cytotoxic CD4+ And CD8+ T Lymphocytes, Generated By Mutant p21-ras (12Val) Peptide Vaccination of a Patient, Recognize 12VAL-Dependent Nested Epitopes Present Within The Vaccine Peptide and Kill Autologous...." page 784 - page 790 --	1-13
X	GB 2253211 A (NORSK HYDRO A.S), 2 Sept 1992 (02.09.92), see page 32 and page 37 Seq. p178 and p180 --	1-13

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

8 December 1998

Date of mailing of the international search report

11-12-1998

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NO 98/00252

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Human Immunology, Volume 55, 1997, Cécile Gouttenfangeas et al, "Differential Binding to Frequent HLA-A Alleles of p21 RAS Derived Peptides Bearing Oncogenic Substitutions at Position 12 or 13", page 117 - page 126, see table 2 --	1-13
X	Int. J. Cancer, Volume 68, 1996, Antonio Juretic et al, "Cytotoxic T-Lymphocyte Responses Against Mutated P21 Ras Peptides: An Analysis of Specific T-Cell-Receptor Gene Usage", page 471 - page 478, see summary --	1-13
A	Eur. J. Immunol., Volume 26, 1996, Scott I. Abrams et al, "Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses" page 435 - page 443 -- -----	1-13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NO98/00252

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-15
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/11/98

International application No.

PCT/NO 98/00252

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9740156 A1	30/10/97	AU 2734397 A	12/11/97

GB 2253211 A	02/09/92	AU 660452 B	29/06/95
		AU 1272992 A	15/09/92
		CA 2077537 A	27/08/92
		EP 0529023 A	03/03/93
		FI 924069 A	11/09/92
		WO 9214756 A	03/09/92
